Search results
9 sty 2023 · Prostate-specific membrane antigen (PSMA)-directed posi-tron emission tomography/computed tomography (PET/CT) is a non-invasive diagnostic technique to image PSMA posi-tive lesions in individuals with prostate cancer. PSMA is a transmembrane protein with an extracellular binding site.
- EANM/SNMMI guideline for PSMA PET/CT Prostate Cancer Imaging 2.0
This document provides guidance and standards for the...
- EANM/SNMMI guideline for PSMA PET/CT Prostate Cancer Imaging 2.0
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands.
5 sty 2023 · Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are...
1 cze 2023 · Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, et al. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
1 sty 2022 · PSMA PET Imaging Protocols and Reporting. The recommended imaging protocols for 68 Ga-PSMA-11 and 18 F-DCFPyL are similar. In short, the administered activity, based on the prescribing information, is 111–259 MBq (3–7 mCi) for 68 Ga-PSMA-11 and 296–370 MBq (8–10 mCi) for 18 F-DCFPyL.
Recently, the European Association of Urology (EAU) guidelines on PCa recommend the use of PSMA-PET imaging for any case of biochemical recurrence after radical prostatectomy (PSA > 0.2 ng/mL), namely if PSMA-PET scan is able to positively influence the subsequent treatment strategy.
This document provides guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging.
